Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-001987-24 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative therapy (LIR).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Oral treatment |
|
| 2 | Experimental | Oral treatment |
|
| 3 | Placebo Comparator | Oral treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NKTR-118 | Drug | 12.5 mg oral tablet once daily |
| |
| NKTR-118 |
| Measure | Description | Time Frame |
|---|---|---|
| Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 | Responder was defined as having at least 3 spontaneous bowel movements (SBMs)/week with at least 1 SBM/week increase over baseline for at least 9 out of the 12 treatment weeks and 3 out of the last 4 treatment weeks during the double-blind treatment period. An SBM is a bowel movement occurring 24 hours or more since the last use of rescue medication. | Baseline (Week 1) to end of treatment (Week 12) |
| Measure | Description | Time Frame |
|---|---|---|
| Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12 | Responder is defined as having at least 3 SBMs/week, with at least 1 SBM/week increase over baseline for at least 9 out of 12 weeks and at least 3 out of the last 4 weeks. | Baseline (Week 1) to end of treatment (Week 12) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Sostek | AstraZeneca Pharmaceuticals, Wilm DE | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Birmingham | Alabama | United States | |||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28059433 | Derived | Webster L, Tummala R, Diva U, Lappalainen J. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation. J Opioid Manag. 2016 Nov/Dec;12(6):405-419. doi: 10.5055/jom.2016.0360. | |
| 27342744 | Derived | Lawson R, King F, Marsh K, Altincatal A, Cimen A. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility. Adv Ther. 2016 Aug;33(8):1331-46. doi: 10.1007/s12325-016-0365-y. Epub 2016 Jun 24. |
| Label | URL |
|---|---|
| Clinical\_Study\_Report\_Synopsis\_D3820C00004 | View source |
Not provided
The study duration was up to 18 weeks, consisting of an initial screening period lasting up to 2 weeks, a 2-week OIC confirmation period, during which the diagnosis of OIC and stability of the opioid regimen were confirmed, a 12-week treatment period, and a follow-up visit 2 weeks after the last dose of study drug.
This multicenter study was conducted in Australia, Germany, Slovakia, and the United States between 14 March 2011 and 16 August 2012.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | NKTR-118 12.5 mg | NKTR-118 12.5 QD, oral treatment |
| FG001 | NKTR-118 25 mg | NKTR-118 25 mg QD, oral treatment |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
25 mg oral tablet once daily |
|
| Placebo | Drug | Oral tablet once daily |
|
| Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours |
| 12 weeks |
| Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12 | 12 weeks |
| Change From Baseline in Degree of Straining | A single-item straining question was asked via the eDiary: "How much did you strain during your bowel movement?" Patients responded on a 5 point Likert scale: 1=Not at all; 2=A little bit; 3=A moderate amount; 4=A great deal; 5=An extreme amount. A negative change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Stool Consistency (Bristol Stool Scale) | Patients rated stool consistency through completion of the BSS after each BM. The 7 stool types are: 1. Separate hard lumps, like nuts (hard to pass); 2. Sausage-shaped, but lumpy; 3. Like sausage, but with cracks on its surface; 4. Like a sausage or snake, smooth and soft; 5. Soft blobs with clear cut edges (passed easily); 6. Fluffy pieces with ragged edges, a mushy stool; 7. Watery, no solid pieces. A positive change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement) | A single-item question on the completeness of evacuation, developed and validated through 1:1 interviews with OIC patients, was asked via the eDiary: "Did you feel like your bowels were completely empty after the bowel movement?" Patients provided a yes or a no response. A positive change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Mean Spontaneous Bowel Movements/Week | The number of spontaneous bowel movements/week was determined from the patient's eDiary. | Baseline (Week 1) to end of treatment (Week 12) |
| Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup | Time to first post-dose laxation without the use of rescue laxatives within the last 24 hours was calculated in hours as: Date/Time of first post-dose laxation without rescue - First dose date/time. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) | The PAC-SYM questionnaire is a 12-item questionnaire that evaluates the severity of symptoms of constipation in 3 domains (stool, rectal, and abdominal symptoms) on a 5-point Likert scale ranging from 0 (absent) to 4 (very severe) in the 2 weeks (14 days) prior to assessment. Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items (ie, symptoms). The range of the domain or total score is 0 (response is 'absent' for each item) to 4 (response is 'very severe' for each item). A negative change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain | The PAC-QOL scale is a 28-item self-report instrument designed to evaluate the burden of constipation on patients' everyday functioning and well-being in the 2 weeks (14 days) prior to assessment. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). The instrument can be used to generate an overall score, but is also reported to assess 4 specific constipation-related domains including: 1) Worries and concerns (11 items), 2) Physical discomfort (4 items), 3) Psychosocial discomfort (8 items), and 4) Satisfaction (5 items). Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items. The range of the domain or total score is 0 (response is 'not at all' for each item) to 4 (response is 'extremely' for each item). A negative change from baseline indicates improvement. | Baseline (Week 1) to end of treatment (Week 12) |
| Calera |
| Alabama |
| United States |
| Research Site | Glendale | Arizona | United States |
| Research Site | Mesa | Arizona | United States |
| Research Site | Phoenix | Arizona | United States |
| Research Site | Tucson | Arizona | United States |
| Research Site | Hot Springs | Arkansas | United States |
| Research Site | Malvern | Arkansas | United States |
| Research Site | Anaheim | California | United States |
| Research Site | Beverly Hills | California | United States |
| Research Site | Burbank | California | United States |
| Research Site | Garden Grove | California | United States |
| Research Site | Laguana Hills | California | United States |
| Research Site | Laguna Hills | California | United States |
| Research Site | Long Beach | California | United States |
| Research Site | Los Gatos | California | United States |
| Research Site | Montebello | California | United States |
| Research Site | National City | California | United States |
| Research Site | Norwalk | California | United States |
| Research Site | Paramount | California | United States |
| Research Site | Sacramento | California | United States |
| Research Site | San Diego | California | United States |
| Research Site | Santa Ana | California | United States |
| Research Site | Denver | Colorado | United States |
| Research Site | Boynton Beach | Florida | United States |
| Research Site | Brooksville | Florida | United States |
| Research Site | DeLand | Florida | United States |
| Research Site | Fort Myers | Florida | United States |
| Research Site | Hialeah | Florida | United States |
| Research Site | Inverness | Florida | United States |
| Research Site | Jacksonville | Florida | United States |
| Research Site | Jackson | Florida | United States |
| Research Site | Jupiter | Florida | United States |
| Research Site | Maitland | Florida | United States |
| Research Site | Miami | Florida | United States |
| Research Site | Naples | Florida | United States |
| Research Site | Orlando | Florida | United States |
| Research Site | Ormond Beach | Florida | United States |
| Research Site | Pembroke Pines | Florida | United States |
| Research Site | Plantation | Florida | United States |
| Research Site | Tamarac | Florida | United States |
| Research Site | Tampa | Florida | United States |
| Research Site | Venice | Florida | United States |
| Research Site | West Palm Beach | Florida | United States |
| Research Site | Winter Park | Florida | United States |
| Research Site | Atlanta | Georgia | United States |
| Research Site | Decatur | Georgia | United States |
| Research Site | Boise | Idaho | United States |
| Research Site | Bloomington | Illinois | United States |
| Research Site | Rockford | Illinois | United States |
| Research Site | Evansville | Indiana | United States |
| Research Site | Greenfield | Indiana | United States |
| Research Site | Indianapolis | Indiana | United States |
| Research Site | West Des Moines | Iowa | United States |
| Research Site | Pikesville | Maryland | United States |
| Research Site | Brockton | Massachusetts | United States |
| Research Site | Kalamazoo | Michigan | United States |
| Research Site | Biloxi | Mississippi | United States |
| Research Site | Saint Joseph | Missouri | United States |
| Research Site | St Louis | Missouri | United States |
| Research Site | Missoula | Montana | United States |
| Research Site | Omaha | Nebraska | United States |
| Research Site | Las Vegas | Nevada | United States |
| Research Site | Trenton | New Jersey | United States |
| Research Site | Albuquerque | New Mexico | United States |
| Research Site | New York | New York | United States |
| Research Site | Charlotte | North Carolina | United States |
| Research Site | Greensboro | North Carolina | United States |
| Research Site | Hickory | North Carolina | United States |
| Research Site | High Point | North Carolina | United States |
| Research Site | Morrisville | North Carolina | United States |
| Research Site | Beavercreek | Ohio | United States |
| Research Site | Cincinnati | Ohio | United States |
| Research Site | Medord | Oregon | United States |
| Research Site | Feasterville | Pennsylvania | United States |
| Research Site | Huntingdon Valley | Pennsylvania | United States |
| Research Site | Levittown | Pennsylvania | United States |
| Research Site | Philadelphia | Pennsylvania | United States |
| Research Site | Yardley | Pennsylvania | United States |
| Research Site | Cumberland | Rhode Island | United States |
| Research Site | Charleston | South Carolina | United States |
| Research Site | Greer | South Carolina | United States |
| Research Site | Orangeburg | South Carolina | United States |
| Research Site | Clarksville | Tennessee | United States |
| Research Site | Austin | Texas | United States |
| Research Site | Dallas | Texas | United States |
| Research Site | Doral | Texas | United States |
| Research Site | Houston | Texas | United States |
| Research Site | North Richland Hills | Texas | United States |
| Research Site | Salt Lake City | Utah | United States |
| Research Site | Spokane | Washington | United States |
| Research Site | Broadmeadow | New South Wales | Australia |
| Research Site | Darlinghurst | New South Wales | Australia |
| Research Site | Port Kembla | New South Wales | Australia |
| Research Site | Westmead | New South Wales | Australia |
| Research Site | Greenslopes | Queensland | Australia |
| Research Site | Adelaide | South Australia | Australia |
| Research Site | Fremantle | Western Australia | Australia |
| Research Site | Nedlands | Western Australia | Australia |
| Research Site | Potsdam | BR | Germany |
| Research Site | Hamburg | Free and Hanseatic City of Hamburg | Germany |
| Research Site | Dietzenbach | Hesse | Germany |
| Research Site | Hüttenberg | Hesse | Germany |
| Research Site | Wetzlar | Hesse | Germany |
| Research Site | Celle | Lower Saxony | Germany |
| Research Site | Hanover | Lower Saxony | Germany |
| Research Site | Schwerin | Mecklenburg-Vorpommern | Germany |
| Research Site | Essen | North Rhine-Westphalia | Germany |
| Research Site | Mainz | Rhineland-Palatinate | Germany |
| Research Site | Dresden | Saxony | Germany |
| Research Site | Leipzig | Saxony | Germany |
| Research Site | Kiel | Schleswig-Holstein | Germany |
| Research Site | Berlin | State of Berlin | Germany |
| Research Site | Banská Bystrica | Slovakia |
| Research Site | Bratislava | Slovakia |
| Research Site | Košice | Slovakia |
| Research Site | Prešov | Slovakia |
| 26535126 | Derived | Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J. 2015 Oct;3(5):471-80. doi: 10.1177/2050640615604543. |
| 24896818 | Derived | Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4. |
| FG002 |
| Placebo |
Placebo QD, oral treatment |
| COMPLETED |
|
| NOT COMPLETED |
|
|
A total of 11 patients (4 patients each in the NKTR-118 25 mg and 12.5 mg groups and 3 patients in the placebo group) had been previously randomized within the NKTR-118 program at a different study center. These patients were excluded from the ITT and Safety analysis sets. Baseline characteristics are summarized based on the ITT analysis set.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | NKTR-118 12.5 mg | NKTR-118 12.5 QD, oral treatment |
| BG001 | NKTR-118 25 mg | NKTR-118 25 mg QD, oral treatment |
| BG002 | Placebo | Placebo QD, oral treatment |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Number | Participants |
| ||||||||||||||||
| Baseline laxative response status | Laxative response status was determined at the screening visit (Visit 1) based on the Baseline Laxative Response Status Questionnaire. Patients were classified as: Laxative Inadequate Responder (LIR: patients who reported moderate, severe, or very severe symptoms in at least 1 of the 4 stool symptom domains); Laxative Adequate Responder (LAR: patients who reported no symptoms or only mild symptoms); and Laxative Unknown Responder (LUR: patients who had not taken laxatives over the previous 2 weeks or who had taken 1 or more laxative classes on <4 days over the previous 2 weeks). | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 | Responder was defined as having at least 3 spontaneous bowel movements (SBMs)/week with at least 1 SBM/week increase over baseline for at least 9 out of the 12 treatment weeks and 3 out of the last 4 treatment weeks during the double-blind treatment period. An SBM is a bowel movement occurring 24 hours or more since the last use of rescue medication. | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Number | Number of patients | Baseline (Week 1) to end of treatment (Week 12) |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12 | Responder is defined as having at least 3 SBMs/week, with at least 1 SBM/week increase over baseline for at least 9 out of 12 weeks and at least 3 out of the last 4 weeks. | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. The LIR subgroup used 1 or more laxative classes for at least 4 days in the 2 weeks prior to entry and reported moderate to very severe symptoms. | Posted | Number | Number of patients | Baseline (Week 1) to end of treatment (Week 12) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Median | 95% Confidence Interval | Hours | 12 weeks |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12 | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | Number of Days | 12 weeks |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Degree of Straining | A single-item straining question was asked via the eDiary: "How much did you strain during your bowel movement?" Patients responded on a 5 point Likert scale: 1=Not at all; 2=A little bit; 3=A moderate amount; 4=A great deal; 5=An extreme amount. A negative change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Stool Consistency (Bristol Stool Scale) | Patients rated stool consistency through completion of the BSS after each BM. The 7 stool types are: 1. Separate hard lumps, like nuts (hard to pass); 2. Sausage-shaped, but lumpy; 3. Like sausage, but with cracks on its surface; 4. Like a sausage or snake, smooth and soft; 5. Soft blobs with clear cut edges (passed easily); 6. Fluffy pieces with ragged edges, a mushy stool; 7. Watery, no solid pieces. A positive change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement) | A single-item question on the completeness of evacuation, developed and validated through 1:1 interviews with OIC patients, was asked via the eDiary: "Did you feel like your bowels were completely empty after the bowel movement?" Patients provided a yes or a no response. A positive change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | Percent days/week | Baseline (Week 1) to end of treatment (Week 12) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Mean Spontaneous Bowel Movements/Week | The number of spontaneous bowel movements/week was determined from the patient's eDiary. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Least Squares Mean | Standard Error | Number of SBMs/week | Baseline (Week 1) to end of treatment (Week 12) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup | Time to first post-dose laxation without the use of rescue laxatives within the last 24 hours was calculated in hours as: Date/Time of first post-dose laxation without rescue - First dose date/time. | The ITT analysis set included all randomized patients, with the exception of patients who were found to have randomized multiple times within the program at different centers. | Posted | Median | 95% Confidence Interval | hours | Baseline (Week 1) to end of treatment (Week 12) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) | The PAC-SYM questionnaire is a 12-item questionnaire that evaluates the severity of symptoms of constipation in 3 domains (stool, rectal, and abdominal symptoms) on a 5-point Likert scale ranging from 0 (absent) to 4 (very severe) in the 2 weeks (14 days) prior to assessment. Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items (ie, symptoms). The range of the domain or total score is 0 (response is 'absent' for each item) to 4 (response is 'very severe' for each item). A negative change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who randomized multiple times at different centers. MMRM analysis includes all patients with baseline and at least 1 post-baseline assessment, while the Ns at Week 12 reflect patients providing data at Week 12. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain | The PAC-QOL scale is a 28-item self-report instrument designed to evaluate the burden of constipation on patients' everyday functioning and well-being in the 2 weeks (14 days) prior to assessment. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). The instrument can be used to generate an overall score, but is also reported to assess 4 specific constipation-related domains including: 1) Worries and concerns (11 items), 2) Physical discomfort (4 items), 3) Psychosocial discomfort (8 items), and 4) Satisfaction (5 items). Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items. The range of the domain or total score is 0 (response is 'not at all' for each item) to 4 (response is 'extremely' for each item). A negative change from baseline indicates improvement. | The ITT analysis set included all randomized patients who had evaluable data at baseline and post-baseline, with the exception of patients who randomized multiple times at different centers. MMRM analysis includes all patients with baseline and at least 1 post-baseline assessment, while the Ns at Week 12 reflect patients providing data at Week 12. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline (Week 1) to end of treatment (Week 12) |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | NKTR-118 12.5 mg | 11 | 211 | 57 | 211 | |||
| EG001 | NKTR-118 25 mg | 7 | 214 | 85 | 214 | |||
| EG002 | Placebo | 11 | 213 | 53 | 213 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ACUTE MYOCARDIAL INFARCTION | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ATRIAL FLUTTER | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
| |
| CORONARY ARTERY DISEASE | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
| |
| MYOCARDIAL INFARCTION | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
| |
| PALPITATIONS | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| FLATULENCE | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| GASTROOESOPHAGEAL REFLUX DISEASE | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| SIGMOIDITIS | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| NON-CARDIAC CHEST PAIN | General disorders | MedDRA 15.0 | Systematic Assessment |
| |
| PYREXIA | General disorders | MedDRA 15.0 | Systematic Assessment |
| |
| CELLULITIS | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| CLOSTRIDIAL INFECTION | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| DIVERTICULITIS | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| PNEUMONIA | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| POST PROCEDURAL INFECTION | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| SEPTIC SHOCK | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| CARDIAC VALVE REPLACEMENT COMPLICATION | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| FOOT FRACTURE | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| LACERATION | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| TENDON INJURY | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| BLOOD POTASSIUM DECREASED | Investigations | MedDRA 15.0 | Systematic Assessment |
| |
| HYPERGLYCAEMIA | Metabolism and nutrition disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HYPOKALAEMIA | Metabolism and nutrition disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HYPONATRAEMIA | Metabolism and nutrition disorders | MedDRA 15.0 | Systematic Assessment |
| |
| MOBILITY DECREASED | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| NON-SMALL CELL LUNG CANCER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 15.0 | Systematic Assessment |
| |
| RENAL CANCER STAGE I | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 15.0 | Systematic Assessment |
| |
| BASILAR MIGRAINE | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| SYNCOPE | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| TRANSIENT ISCHAEMIC ATTACK | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| RENAL FAILURE ACUTE | Renal and urinary disorders | MedDRA 15.0 | Systematic Assessment |
| |
| POSTMENOPAUSAL HAEMORRHAGE | Reproductive system and breast disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HYPOTENSION | Vascular disorders | MedDRA 15.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN UPPER | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| FLATULENCE | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| NAUSEA | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| ABDOMINAL DISTENSION | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| VOMITING | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
| |
| UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| URINARY TRACT INFECTION | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
| |
| FALL | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
| |
| BACK PAIN | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
| |
| DIZZINESS | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HEADACHE | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
| |
| HYPERHIDROSIS | Skin and subcutaneous tissue disorders | MedDRA 15.0 | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Mark Sostek | AstraZeneca | ClinicalTrialTransparency@astrazeneca.com |
| ID | Term |
|---|---|
| D000079689 | Opioid-Induced Constipation |
| ID | Term |
|---|---|
| D003248 | Constipation |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000589308 | naloxegol |
Not provided
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| Other |
|
| Laxative Adequate Response (LAR) |
|
| Laxative Unknown Response (LUR) |
|
| Cochran-Mantel-Haenszel |
| 0.001 |
| Risk Ratio (RR) |
| 1.509 |
| 2-Sided |
| 95 |
| 1.168 |
| 1.949 |
| No |
| Superiority or Other |
| Participants |
|
|
|
|
|
|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
|
|
|
|
Placebo QD, oral treatment |
|
|
|
NKTR-118 25 mg QD, oral treatment |
| OG002 | Placebo | Placebo QD, oral treatment |
|
|
|